Pfiz­er of­fers 3rd round of JAK da­ta, this time in kids. Can it com­pete?

Pfiz­er has re­leased the 3rd round of large and late-stage da­ta for their JAK in­hibitor and they say — well, they say pret­ty much what the first 2 stud­ies said, just in a new set of pa­tients.

The lat­est study, called JADE TEEN, was the first to study their JAK in­hibitor abroc­i­tinib ex­clu­sive­ly on chil­dren and ado­les­cents, test­ing it against place­bo in just un­der 300 atopic der­mati­tis pa­tients age 12 to 18. The youth pop­u­la­tion for AD is sig­nif­i­cant, with be­tween 15% and 20% of chil­dren af­fect­ed an­nu­al­ly by the in­flam­ma­to­ry con­di­tion world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER